Table 4.

Univariate Cox regression analysis of the impact of the lncRNA signature and other clinicopathological features on OS in the three NSCLC patient cohorts

Parameters	Training cohort		Validation cohort		Independent cohort
	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Signature
(High vs low)	3.20 (0.58–1.65)	< 0.001	2.84 (1.59–5.07)	< 0.001	2.84 (1.59–5.07)	0.009
Age
(≥ 60 vs < 60)	1.24 (0.73–2.09)	0.417	1.13 (0.67–1.91)	0.330	0.88 (0.36–2.13)	0.782
Gender
(Male vs female)	0.86 (0.48–1.52)	0.619	1.24 (0.63–2.41)	0.050	0.98 (0.37–2.57)	0.978
TNM stages
(III vs II vs I)	1.67 (1.28–2.19)	< 0.001	1.70 (1.30–2.23)	0.001	1.74 (1.04–2.89)	0.031
Histological type
(ADC vs SCC)	1.30 (0.74–2.29)	0.346	1.39 (0.82–2.36)	0.589	0.53 (0.15–1.83)	0.320
Tumor size
(≥ 5 cm vs < 5 cm)	1.17 (0.69–1.98)	0.545	1.15 (0.68–1.95)	0.017	3.00 (1.00–9.00)	0.048
Differentiation
(Poor vs well/mod)	0.98 (0.58–1.65)	0.951	1.43 (0.85–2.42)	0.079	1.80 (0.74–4.32)	0.188
Lymph metastasis
(Yes vs no)	1.44 (0.86–2.43)	0.163	0.73 (0.43–1.24)	0.025	1.38 (0.46–4.14)	0.561
Smoking history
(Yes vs no)	0.91 (0.54–1.54)	0.736	1.63 (0.92–2.91)	0.024	1.11 (0.46–2.68)	0.812
Fam. cancer hist.
(Yes vs no)	1.04 (0.52–2.06)	0.899	1.18 (0.58–2.42)	0.580	0.47 (2.97–7.64)	0.618

Italic P values represent the statistic significance

Fam. cancer hist. Family cancer history